Intervention 2

Small molecule

SSultan Qaboos University

Intervention 2 is one of 28 small molecule programs targeting Delirium. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

DeliriumActive, not recruiting

DeliriumPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

167 competitors in Delirium

#DrugCompanyPhaseTrials

Ritalin

Novartis

Phase 3

1 2

Lidocaine IV

KKasr El Aini Hospital

Phase 3

1 3

Physostigmine

AstraZeneca

Phase 3

1 4

Rozerem

Takeda

Preclinical

6 5

Inapsine

Alnylam Pharmaceuticals

Preclinical

1 6

Anerem

AAcacia Pharma Ltd

Preclinical

7 7

Spravato

WWim Janssens

Preclinical

4 8

Raldesy

PPragma

Preclinical

3 9

Bridion

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

2 10

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Delirium1 trial

The Use of Melatonin for Delirium Prevention in Medically Hospitalized Patients

Recruiting·SSultan Qaboos University·Phase 2/3·NCT06509191·240 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Intervention 2. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intervention 2 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intervention 2. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sultan Qaboos University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: SSultan Qaboos University

Intervention 2

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Delirium1 trial

References

Drug Info

Quick Facts

Related News